<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          Chinadaily.com.cn
           
          Go Adv Search

          Novo Nordisk has innovative prescription for expansion

          Updated: 2011-11-02 14:27

          By Liu Jie (China Daily)

            Comments() Print Mail Large Medium  Small

          Novo Nordisk has innovative prescription for expansion

          Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk A/S. [Photo/ China Daily]

          BEIJING - The world's largest insulin producer, Novo Nordisk A/S, said it would not pursue mergers and acquisitions (M&A) in China but would instead expand by strengthening its research and development (R&D) activity, building manufacturing facilities and enhancing education.

          "A few multinational companies made acquisitions (in China) to get entry into the generic medication and (over-the-counter) business.

          "Novo Nordisk is another kind of company. We want to concentrate on innovative new drugs," Ronald Frank Christie, senior vice-president of Novo Nordisk and president of Novo Nordisk (China) Pharmaceuticals Co Ltd, said on Monday.

          According to Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk A/S, the Denmark-based company has made "substantial" investments in China in R&D, manufacturing and education.

          He said the company will "continue to invest in the emerging market, also the fastest-growing market for Novo Nordisk".

          The drugmaker, which has focused on diabetes for more than 80 years, said last year it would invest more than $100 million to expand its R&D center in Beijing and double its R&D staff to 200 within five years.

          The center in Beijing is Novo Nordisk's largest such facility outside its headquarters in Copenhagen.

          "We are not interested in bringing in generic (products). We are only interested in bringing new drugs to the market, to make a difference," said Christie.

          Novo Nordisk, which produces two-thirds of the insulin used in China, also announced in 2008 it would invest $400 million to build a manufacturing base in Tianjin, which is expected to go into full operation in 2012. That base would be the largest manufacturing facility for the company outside its home market of Denmark.

          In addition to meeting local demand, the Tianjin base will also export products.

          "We believe that the capacity of manufacturing (in Tianjin) will supply our demand at least for the next three or four years," said Sorensen. "Perhaps, two years from now, we may have to consider further investment, but it's too early to talk about that."

          Novo Nordisk has sought to provide consumer education and offer training to local doctors. In addition to constant community-training courses, it linked up with the Ministry of Health and Chinese academic institutes to hold international diabetes forums and train grassroots medical care practitioners.

          Statistics from the Ministry of Health show that nearly 100 million Chinese have diabetes. The Chinese diabetes drug market will increase to more than $2.8 billion by 2015 from $642 million in 2009, the International Market Analysis Research and Consulting Group said in a report.

          According to medical care research company IMS Health, Novo Nordisk, US-based Eli Lilly and Co and French drugmaker Sanofi AS hold about 90 percent of China's insulin market.

          Some international pharmaceutical companies, such as Swiss drugmaker Novartis AG and Novo Nordisk's archrival Sanofi, were engaged in M&As with local companies in recent years.

          "Different companies have different choices, given their different competitive edges.

          "Innovation-focused drug producers in China may face the challenge of high prices compared with generic products and difficulties in getting their products on the nation's essential drug list or into the medical insurance system," said Guo Fanli, an analyst from the domestic research company China Investment Consulting.

           

          主站蜘蛛池模板: jizz视频在线观看| 欧美在线观看网址| 91中文字幕一区二区| 中文字幕久久国产精品| 无码人妻丝袜在线视频| 国产第一区二区三区精品| 色成人亚洲| 非会员区试看120秒6次| 玩弄放荡人妻少妇系列| 少妇激情一区二区三区视频小说| 一级成人欧美一区在线观看| 无码国产偷倩在线播放| 97视频精品全国在线观看| 国产av一区二区午夜福利| 性姿势真人免费视频放| 亚洲精品国产自在现线最新| 狠狠人妻久久久久久综合九色 | 国产成人精品a视频| 99久久国产成人免费网站| 无码毛片一区二区本码视频| 国产成人免费永久在线平台| 成人AV无码一区二区三区| 久久天天躁狠狠躁夜夜躁2o2o| 国产99视频精品免视看9| 精品理论一区二区三区| 亚洲精品美女一区二区| 亚洲色偷偷偷综合网| 国产卡一卡二卡三免费入口| 少妇又紧又色又爽又刺激视频| 国产蜜臀av在线一区二区| 人妻av一区二区三区av免费| 久久久久青草线蕉亚洲| 日本中文一二区有码在线| 无码人妻专区免费视频| 亚洲国产成人综合精品| 亚洲欧洲精品国产区| 办公室强奷漂亮少妇同事| 久久亚洲色WWW成人欧美 | 69精品丰满人妻无码视频a片| 亚洲丰满熟女一区二区蜜桃| 国产v亚洲v天堂a无码99|